董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Briggs Morrison | 男 | Director | 67 | 5.64万美元 | 13.91 | 2026-03-27 |
| Daniel J. Hicklin | 男 | Director,President and Chief Executive Officer | 63 | 159.64万美元 | 258.11 | 2026-03-27 |
| Luke Evnin | 男 | Chairman of the Board and Independent Director | 62 | 8.87万美元 | 9.25 | 2026-03-27 |
| Michael Sherman | 男 | Independent Director | 59 | 7.14万美元 | 9.25 | 2026-03-27 |
| Anil Singhal | 男 | Independent Director | 73 | 9.53万美元 | 3.84 | 2026-03-27 |
| Meeta Chatterjee | 女 | Independent Director | 71 | 6.32万美元 | 8.86 | 2026-03-27 |
| Michael B. Atkins | 男 | Independent Director | 71 | 11.19万美元 | 8.02 | 2026-03-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel J. Hicklin | 男 | Director,President and Chief Executive Officer | 63 | 159.64万美元 | 258.11 | 2026-03-27 |
| Steven Bloom | 男 | Chief Business Officer | 65 | 未披露 | 未持股 | 2026-03-27 |
| Michael Urban | 男 | Principal Financial Officer and Principal Accounting Officer | 45 | 未披露 | 10.43 | 2026-03-27 |
董事简历
中英对照 | 中文 | 英文- Briggs Morrison
-
Briggs Morrison，目前担任MPM资本的董事总经理，这是一家专注于医疗保健的风险投资公司，自2015年6月起任职。他曾在上市公司阿斯利康 PLC担任全球药物开发执行副总裁兼首席医疗官，于2012年1月至2015年6月期间领导公司的全球后期开发组织，并担任阿斯利康高级管理团队成员。此前，他曾于2007年至2012年1月在上市公司辉瑞公司担任过多个职位，最终被任命为辉瑞人类健康业务的医疗事务、安全和法规事务主管，还曾在默克制药公司的一个部门默沙东TERM2 Research Laboratories担任越来越多的职责，并于1995年至2007年升任肿瘤学临床科学副总裁，负责所有新型抗癌药物的临床开发。莫里森博士曾担任TransCelerate BioPharma Inc.的董事会主席，该公司是一家行业资助公司，负责改进临床试验的各个方面，2014年至2015年期间，他是FDA赞助的临床试验转化计划CTTI执行委员会的成员，并且是Arvinas、Oncorus和Repare Therapeutics的董事会成员，这三家公司都是一家上市公司，以及几家私营公司的董事会成员。此前，他曾担任Codiak Biosciences和NextCure Therapeutics的董事会成员。Morrison博士在乔治敦大学获得生物学学士学位，并在康涅狄格大学获得医学博士学位。
Briggs Morrison has served as a member of Werewolf Therapeutics, Inc. board of directors since November 2019. He has served as Executive Partner at MPM Capital since June 2015, and as the Chief Executive Officer and a member of the board of directors of Crossbow Therapeutics, Inc., a privately held biotechnology company, since February 2022. Previously, he served as President, Head of Research and Development, of Syndax Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from February 2022 to April 2023, and prior to that was the Chief Executive Officer of Syndax Pharmaceuticals, Inc., from June 2015 to January 2022. Dr. Morrison has served as a member of the board of directors of Arvinas Inc. since June 2018, and CRISPR Therapeutics AG since June 2025, each of which is a publicly traded biopharmaceutical company. Dr. Morrison previously served as a member of the board of directors of Syndax Pharmaceuticals, Inc., from July 2015 to May 2024, Carisma Therapeutics Inc. from July 2020 to October 2025, NextCure Inc. from March 2019 to April 2021, Codiak Biosciences Inc. from February 2018 to April 2021, Oncorus, Inc. from April 2016 to April 2021, and Repare Therapeutics Inc. from June 2017 to August 2024, each of which was a publicly traded biopharmaceutical company. He also serves as a member of the board of directors of several privately held biotechnology companies. Previously, Dr. Morrison was the Chief Medical Officer and Head of Global Medicines Development at AstraZeneca plc from January 2012 to June 2015. Before joining AstraZeneca, he held several positions at Pfizer Inc., including Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business. Dr. Morrison also previously held several positions at Merck Research Laboratories, a division of Merck & Co., Inc.,including Vice President, Clinical Sciences, Oncology. He was a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by the FDA and is on the board of the Alliance for Clinical Research Excellence and Safety. Dr. Morrison has a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut Medical School. He completed residency training in internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana Farber Cancer Institute. - Briggs Morrison，目前担任MPM资本的董事总经理，这是一家专注于医疗保健的风险投资公司，自2015年6月起任职。他曾在上市公司阿斯利康 PLC担任全球药物开发执行副总裁兼首席医疗官，于2012年1月至2015年6月期间领导公司的全球后期开发组织，并担任阿斯利康高级管理团队成员。此前，他曾于2007年至2012年1月在上市公司辉瑞公司担任过多个职位，最终被任命为辉瑞人类健康业务的医疗事务、安全和法规事务主管，还曾在默克制药公司的一个部门默沙东TERM2 Research Laboratories担任越来越多的职责，并于1995年至2007年升任肿瘤学临床科学副总裁，负责所有新型抗癌药物的临床开发。莫里森博士曾担任TransCelerate BioPharma Inc.的董事会主席，该公司是一家行业资助公司，负责改进临床试验的各个方面，2014年至2015年期间，他是FDA赞助的临床试验转化计划CTTI执行委员会的成员，并且是Arvinas、Oncorus和Repare Therapeutics的董事会成员，这三家公司都是一家上市公司，以及几家私营公司的董事会成员。此前，他曾担任Codiak Biosciences和NextCure Therapeutics的董事会成员。Morrison博士在乔治敦大学获得生物学学士学位，并在康涅狄格大学获得医学博士学位。
- Briggs Morrison has served as a member of Werewolf Therapeutics, Inc. board of directors since November 2019. He has served as Executive Partner at MPM Capital since June 2015, and as the Chief Executive Officer and a member of the board of directors of Crossbow Therapeutics, Inc., a privately held biotechnology company, since February 2022. Previously, he served as President, Head of Research and Development, of Syndax Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from February 2022 to April 2023, and prior to that was the Chief Executive Officer of Syndax Pharmaceuticals, Inc., from June 2015 to January 2022. Dr. Morrison has served as a member of the board of directors of Arvinas Inc. since June 2018, and CRISPR Therapeutics AG since June 2025, each of which is a publicly traded biopharmaceutical company. Dr. Morrison previously served as a member of the board of directors of Syndax Pharmaceuticals, Inc., from July 2015 to May 2024, Carisma Therapeutics Inc. from July 2020 to October 2025, NextCure Inc. from March 2019 to April 2021, Codiak Biosciences Inc. from February 2018 to April 2021, Oncorus, Inc. from April 2016 to April 2021, and Repare Therapeutics Inc. from June 2017 to August 2024, each of which was a publicly traded biopharmaceutical company. He also serves as a member of the board of directors of several privately held biotechnology companies. Previously, Dr. Morrison was the Chief Medical Officer and Head of Global Medicines Development at AstraZeneca plc from January 2012 to June 2015. Before joining AstraZeneca, he held several positions at Pfizer Inc., including Head, Medical Affairs, Safety and Regulatory Affairs for Pfizer's human health business. Dr. Morrison also previously held several positions at Merck Research Laboratories, a division of Merck & Co., Inc.,including Vice President, Clinical Sciences, Oncology. He was a member of the executive committee of the Clinical Trials Transformation Initiative sponsored by the FDA and is on the board of the Alliance for Clinical Research Excellence and Safety. Dr. Morrison has a B.S. in biology from Georgetown University and an M.D. from the University of Connecticut Medical School. He completed residency training in internal medicine at Massachusetts General Hospital and a fellowship in medical oncology at the Dana Farber Cancer Institute.
- Daniel J. Hicklin
-
Daniel J.Hicklin自2019年8月起担任我们的总裁兼首席执行官。Hicklin博士于2017年10月创立了Werewolf Therapeutics，并担任顾问，直到被任命为我们的总裁兼首席执行官。此前，Hicklin博士是私营生物技术公司Potenza Therapeutics，Inc.的创始人，并于2014年4月至2018年12月被Astellas Pharma Inc.收购之前担任其总裁兼首席执行官。Hicklin从2013年8月到2014年2月担任Costim Pharmaceuticals，Inc.（一家私营生物技术公司，2014年2月被Novartis收购）总裁和首席科学官。Hicklin博士还于2014年至2019年12月担任执行合伙人，并自2020年1月起担任MPM Capital的顾问。加入Costim Pharmaceuticals之前，Hicklin在Merck Research Laboratories（前身为Schering-Plough Research Institute，被Merck收购之前）担任多个职位，包括领导肿瘤学生物制剂战略和免疫调节发现团队。Hicklin博士此前还在Imclone Systems Incorporated担任过多个职位，包括Vice President、实验治疗。Hicklin博士曾担任多家私营生物技术公司的董事会成员。Hicklin博士目前还在Mark Foundation for Cancer Research的行业咨询委员会任职。Hicklin博士拥有纽约医学院（New York Medical College）的微生物学和免疫学硕士学位和博士学位，在那里他与Soldano Ferrone博士一起接受培训，并获得爱荷华大学（University of Iowa）的B.S.学位。
Daniel J. Hicklin has served on Werewolf Therapeutics, Inc. board of directors since October 2017. Dr. Hicklin has also served as Werewolf Therapeutics, Inc. President and Chief Executive Officer since August 2019. Dr. Hicklin founded Werewolf Therapeutics in October 2017 and served as a consultant until his appointment as Werewolf Therapeutics, Inc. President and Chief Executive Officer. Dr. Hicklin also served as an Executive Partner at MPM Capital from 2014 to December 2019 and an advisor from January 2020 to December 2022. Previously, Dr. Hicklin was a founder of Potenza Therapeutics, Inc., a privately held biotechnology company, and served as its President and Chief Executive Officer from April 2014 until its acquisition by Astellas Pharma Inc. in December 2018. From August 2013 until February 2014, Dr. Hicklin was President and Chief Scientific Officer of CoStim Pharmaceuticals, Inc., a privately held biotechnology company that was acquired by Novartis in February 2014. Prior to joining CoStim Pharmaceuticals, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering Plough Research Institute prior to its acquisition by Merck), including leading its Biologics Strategy for Oncology and the Immuno Modulation Discovery team. Dr. Hicklin also previously held several positions at Imclone Systems Incorporated, including Vice President, Experimental Therapeutics. Dr. Hicklin has served as a member of the board of directors of several private biotechnology companies. Dr. Hicklin also currently serves on the Industry Advisory Committee for The Mark Foundation for Cancer Research. Dr. Hicklin holds an M.S. and Ph.D. in Microbiology and Immunology from New York Medical College, where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa. - Daniel J.Hicklin自2019年8月起担任我们的总裁兼首席执行官。Hicklin博士于2017年10月创立了Werewolf Therapeutics，并担任顾问，直到被任命为我们的总裁兼首席执行官。此前，Hicklin博士是私营生物技术公司Potenza Therapeutics，Inc.的创始人，并于2014年4月至2018年12月被Astellas Pharma Inc.收购之前担任其总裁兼首席执行官。Hicklin从2013年8月到2014年2月担任Costim Pharmaceuticals，Inc.（一家私营生物技术公司，2014年2月被Novartis收购）总裁和首席科学官。Hicklin博士还于2014年至2019年12月担任执行合伙人，并自2020年1月起担任MPM Capital的顾问。加入Costim Pharmaceuticals之前，Hicklin在Merck Research Laboratories（前身为Schering-Plough Research Institute，被Merck收购之前）担任多个职位，包括领导肿瘤学生物制剂战略和免疫调节发现团队。Hicklin博士此前还在Imclone Systems Incorporated担任过多个职位，包括Vice President、实验治疗。Hicklin博士曾担任多家私营生物技术公司的董事会成员。Hicklin博士目前还在Mark Foundation for Cancer Research的行业咨询委员会任职。Hicklin博士拥有纽约医学院（New York Medical College）的微生物学和免疫学硕士学位和博士学位，在那里他与Soldano Ferrone博士一起接受培训，并获得爱荷华大学（University of Iowa）的B.S.学位。
- Daniel J. Hicklin has served on Werewolf Therapeutics, Inc. board of directors since October 2017. Dr. Hicklin has also served as Werewolf Therapeutics, Inc. President and Chief Executive Officer since August 2019. Dr. Hicklin founded Werewolf Therapeutics in October 2017 and served as a consultant until his appointment as Werewolf Therapeutics, Inc. President and Chief Executive Officer. Dr. Hicklin also served as an Executive Partner at MPM Capital from 2014 to December 2019 and an advisor from January 2020 to December 2022. Previously, Dr. Hicklin was a founder of Potenza Therapeutics, Inc., a privately held biotechnology company, and served as its President and Chief Executive Officer from April 2014 until its acquisition by Astellas Pharma Inc. in December 2018. From August 2013 until February 2014, Dr. Hicklin was President and Chief Scientific Officer of CoStim Pharmaceuticals, Inc., a privately held biotechnology company that was acquired by Novartis in February 2014. Prior to joining CoStim Pharmaceuticals, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering Plough Research Institute prior to its acquisition by Merck), including leading its Biologics Strategy for Oncology and the Immuno Modulation Discovery team. Dr. Hicklin also previously held several positions at Imclone Systems Incorporated, including Vice President, Experimental Therapeutics. Dr. Hicklin has served as a member of the board of directors of several private biotechnology companies. Dr. Hicklin also currently serves on the Industry Advisory Committee for The Mark Foundation for Cancer Research. Dr. Hicklin holds an M.S. and Ph.D. in Microbiology and Immunology from New York Medical College, where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa.
- Luke Evnin
-
Luke Evnin是Turmeric Acquisition Corp.的首席执行官。Evnin博士拥有30多年的医疗投资经验，是MPM Capital的联合创始人兼董事总经理。叶夫宁博士于1997与M.D。的Ansbert Gadicke共同创立了MPM，并于1999开设了旧金山办事处。叶夫宁博士发现并推动突破性的药物发现的热情激发了他的工作和MPM团队的工作，MPM团队一直是建立Bioprin制药等公司的推动力。诺华收购的CoStim制药、Epizyme、默克收购的Idenix制药、辉瑞收购的Idun制药、Pacira制药、Pharmasset（吉利德收购）、Potenza Therapeutics（阿斯特拉斯制药收购）和Radius Health。埃夫宁博士是主要投资者，曾在MPM的多个投资公司（包括CoStim、Idun和Pacira）的董事会任职。在他的职业生涯中，他曾在30多个董事会任职，其中包括9家上市公司。在过去七年中，作为MPM活动的一个关键方面，Evnin博士一直是七家MPM投资组合公司的联合创始人，包括Amphivena Therapeutics、Blade Therapeutics、Harpoon Therapeutics、Potenza Therapeutics、Maverick Therapeutics、Tizona Therapeutics和狼人Therapeutics。他以发明家的身份为其中几家公司以及MPM投资组合公司Oncorus做出了贡献，目前他在Oncorus担任董事会成员。鉴于MPM在资助和建立可能对全球癌症护理和治疗产生重大影响的公司方面所做的新颖工作，埃夫宁博士是2017年全球肿瘤远见奖的共同获得者。他还致力于与硬皮病研究基金会合作，自2002以来担任主席。在共同创立MPM之前，他在AcEL合作伙伴身上磨练了自己的技能，他专注于新兴的医疗保健公司。叶夫宁博士在旧金山加利福尼亚大学的生物化学系进行了他的技术培训，并开始了他对疾病治疗的兴趣。在那里他获得了博士学位，他对药物发现的热情从普林斯顿大学获得了他的分子生物学学士学位。
Luke Evnin is a co founder of Werewolf Therapeutics, Inc., served as Werewolf Therapeutics, Inc. President and Chief Executive Officer from December 2017 until August 2019, and has served on Werewolf Therapeutics, Inc. board of directors since October 2017 and as chairman of the board of directors since August 2019. Dr. Evnin co founded MPM Capital, an early stage life sciences venture investing firm, in 1997, where he currently serves as Managing Director. As a component of his MPM activities, Dr. Evnin has been a co founder and served as chairman of the board for multiple MPM portfolio companies. Dr. Evnin has also served on the boards of directors of a number of public and private companies over his venture capital career and currently serves, on behalf of MPM Capital, as a director for multiple private companies. Prior to co founding MPM Capital, Dr. Evnin spent seven years as a venture capitalist at Accel Partners. Dr. Evnin previously served as Chief Executive Officer of Turmeric Acquisition Corp., a publicly traded special purposes acquisition company formed by MPM Capital from August 2020 through April 2023. In 2015, Dr. Evnin co founded Harpoon Therapeutics, Inc., a publicly held immunotherapy company, and served as chair of its board of directors until July 2020. Dr. Evnin served on the board of directors of Oncorus, Inc., a publicly traded biotechnology company, from March 2016 until June 2023. Dr. Evnin serves as chairman of the board of directors of the Scleroderma Research Foundation, a not for profit entity. Dr. Evnin holds an A.B. in molecular biology from Princeton University and a Ph.D. in biochemistry from the University of California, San Francisco. - Luke Evnin是Turmeric Acquisition Corp.的首席执行官。Evnin博士拥有30多年的医疗投资经验，是MPM Capital的联合创始人兼董事总经理。叶夫宁博士于1997与M.D。的Ansbert Gadicke共同创立了MPM，并于1999开设了旧金山办事处。叶夫宁博士发现并推动突破性的药物发现的热情激发了他的工作和MPM团队的工作，MPM团队一直是建立Bioprin制药等公司的推动力。诺华收购的CoStim制药、Epizyme、默克收购的Idenix制药、辉瑞收购的Idun制药、Pacira制药、Pharmasset（吉利德收购）、Potenza Therapeutics（阿斯特拉斯制药收购）和Radius Health。埃夫宁博士是主要投资者，曾在MPM的多个投资公司（包括CoStim、Idun和Pacira）的董事会任职。在他的职业生涯中，他曾在30多个董事会任职，其中包括9家上市公司。在过去七年中，作为MPM活动的一个关键方面，Evnin博士一直是七家MPM投资组合公司的联合创始人，包括Amphivena Therapeutics、Blade Therapeutics、Harpoon Therapeutics、Potenza Therapeutics、Maverick Therapeutics、Tizona Therapeutics和狼人Therapeutics。他以发明家的身份为其中几家公司以及MPM投资组合公司Oncorus做出了贡献，目前他在Oncorus担任董事会成员。鉴于MPM在资助和建立可能对全球癌症护理和治疗产生重大影响的公司方面所做的新颖工作，埃夫宁博士是2017年全球肿瘤远见奖的共同获得者。他还致力于与硬皮病研究基金会合作，自2002以来担任主席。在共同创立MPM之前，他在AcEL合作伙伴身上磨练了自己的技能，他专注于新兴的医疗保健公司。叶夫宁博士在旧金山加利福尼亚大学的生物化学系进行了他的技术培训，并开始了他对疾病治疗的兴趣。在那里他获得了博士学位，他对药物发现的热情从普林斯顿大学获得了他的分子生物学学士学位。
- Luke Evnin is a co founder of Werewolf Therapeutics, Inc., served as Werewolf Therapeutics, Inc. President and Chief Executive Officer from December 2017 until August 2019, and has served on Werewolf Therapeutics, Inc. board of directors since October 2017 and as chairman of the board of directors since August 2019. Dr. Evnin co founded MPM Capital, an early stage life sciences venture investing firm, in 1997, where he currently serves as Managing Director. As a component of his MPM activities, Dr. Evnin has been a co founder and served as chairman of the board for multiple MPM portfolio companies. Dr. Evnin has also served on the boards of directors of a number of public and private companies over his venture capital career and currently serves, on behalf of MPM Capital, as a director for multiple private companies. Prior to co founding MPM Capital, Dr. Evnin spent seven years as a venture capitalist at Accel Partners. Dr. Evnin previously served as Chief Executive Officer of Turmeric Acquisition Corp., a publicly traded special purposes acquisition company formed by MPM Capital from August 2020 through April 2023. In 2015, Dr. Evnin co founded Harpoon Therapeutics, Inc., a publicly held immunotherapy company, and served as chair of its board of directors until July 2020. Dr. Evnin served on the board of directors of Oncorus, Inc., a publicly traded biotechnology company, from March 2016 until June 2023. Dr. Evnin serves as chairman of the board of directors of the Scleroderma Research Foundation, a not for profit entity. Dr. Evnin holds an A.B. in molecular biology from Princeton University and a Ph.D. in biochemistry from the University of California, San Francisco.
- Michael Sherman
-
Michael Sherman，自2021年5月起担任董事会董事。Sherman先生此前曾于2019年4月至2023年7月担任上市生物制药公司Chimerix, Inc.的首席执行官和董事会成员，并于2023年8月至2025年4月担任Chimerix的董事会主席。在此之前，Sherman先生曾于2016年6月至2018年12月在生物制药公司Endocyte, Inc.担任总裁、首席执行官和董事会成员，当时该公司被诺华收购。Sherman先生于2006年加入Endocyte，在成为首席执行官之前曾担任其首席财务官和首席运营官。在加入Endocyte之前，Sherman先生曾担任多个行政职务，包括担任Guidant Corporation的财务和战略规划副总裁，该公司已被波士顿科学国际有限公司收购。谢尔曼先生目前担任一家私营生命科学公司的董事会成员。他还于2020年4月起至2020年12月被远藤制药收购前一直担任BioSpecifics生物，Inc.的董事会成员，并于2012年1月至2022年12月担任印第安纳波利斯儿童博物馆的董事会主席。Sherman先生拥有DePauw大学经济学学士学位和达特茅斯大学塔克商学院MBA学位，并以塔克学者的身份毕业。
Michael Sherman has served on Werewolf Therapeutics, Inc. board of directors since May 2021. Mr. Sherman previously served from April 2019 to July 2023 as Chief Executive Officer and a member of the board of directors of Chimerix, Inc., a publicly traded biopharmaceutical company, and as chair of the board of directors of Chimerix from August 2023 to April 2025. Prior to that, Mr. Sherman served as President, Chief Executive Officer, and member of the board of directors of Endocyte, Inc., a biopharmaceutical company, from June 2016 until December 2018, when it was acquired by Novartis. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by Boston Scientific Corporation. Mr. Sherman has served on the board of directors of Aktis Oncology, Inc., a publicly traded company, since August 2025. Mr. Sherman also currently serves on the board of directors of a privately held life sciences company. He has also served on the board of directors of Biospecifics Technologies, Inc. from April 2020 until its acquisition by Endo Pharmaceuticals in December 2020, and he served as chair of the board of directors of the Children's Museum of Indianapolis from January 2012 until December 2022. - Michael Sherman，自2021年5月起担任董事会董事。Sherman先生此前曾于2019年4月至2023年7月担任上市生物制药公司Chimerix, Inc.的首席执行官和董事会成员，并于2023年8月至2025年4月担任Chimerix的董事会主席。在此之前，Sherman先生曾于2016年6月至2018年12月在生物制药公司Endocyte, Inc.担任总裁、首席执行官和董事会成员，当时该公司被诺华收购。Sherman先生于2006年加入Endocyte，在成为首席执行官之前曾担任其首席财务官和首席运营官。在加入Endocyte之前，Sherman先生曾担任多个行政职务，包括担任Guidant Corporation的财务和战略规划副总裁，该公司已被波士顿科学国际有限公司收购。谢尔曼先生目前担任一家私营生命科学公司的董事会成员。他还于2020年4月起至2020年12月被远藤制药收购前一直担任BioSpecifics生物，Inc.的董事会成员，并于2012年1月至2022年12月担任印第安纳波利斯儿童博物馆的董事会主席。Sherman先生拥有DePauw大学经济学学士学位和达特茅斯大学塔克商学院MBA学位，并以塔克学者的身份毕业。
- Michael Sherman has served on Werewolf Therapeutics, Inc. board of directors since May 2021. Mr. Sherman previously served from April 2019 to July 2023 as Chief Executive Officer and a member of the board of directors of Chimerix, Inc., a publicly traded biopharmaceutical company, and as chair of the board of directors of Chimerix from August 2023 to April 2025. Prior to that, Mr. Sherman served as President, Chief Executive Officer, and member of the board of directors of Endocyte, Inc., a biopharmaceutical company, from June 2016 until December 2018, when it was acquired by Novartis. Mr. Sherman joined Endocyte in 2006 and served as its Chief Financial Officer and Chief Operating Officer prior to becoming Chief Executive Officer. Prior to joining Endocyte, Mr. Sherman served in various executive roles, including as vice president of finance and strategic planning for Guidant Corporation, which was acquired by Boston Scientific Corporation. Mr. Sherman has served on the board of directors of Aktis Oncology, Inc., a publicly traded company, since August 2025. Mr. Sherman also currently serves on the board of directors of a privately held life sciences company. He has also served on the board of directors of Biospecifics Technologies, Inc. from April 2020 until its acquisition by Endo Pharmaceuticals in December 2020, and he served as chair of the board of directors of the Children's Museum of Indianapolis from January 2012 until December 2022.
- Anil Singhal
-
Anil Singhal，自2025年2月起担任Werewolf Therapeutics，Inc.董事会成员。自2021年1月以来，Singhal博士一直担任私营生物技术公司Trishula Therapeutics，Inc.的总裁兼首席执行官，他还担任该公司的董事会成员。从2019年5月到2020年9月，Singhal博士担任Adicet Bio, Inc.或Adicet Bio的总裁兼首席执行官和董事会成员，在那里他带领这家当时的私营生物技术公司提交了首个肿瘤学研究性新药申请，并与RESTAR Bio，Inc.合并，这导致Adicet Bio成为一家上市公司。Singhal博士在合并后的2020年9月至2021年2月期间曾短暂担任Adicet Bio的顾问。Singhal博士还曾于2013年1月至2018年3月担任上市制药公司艾伯维公司（AbbVie Inc.）的早期肿瘤学开发副总裁。此外，从2018年7月到2024年9月，Singhal博士是TriSalus Inc.的董事会成员，该公司是一家于2023年上市的生物技术公司。Singhal博士是美国癌症研究协会的成员，他于2005年加入该协会，也是美国临床肿瘤学会的成员，他于2007年加入该协会。Singhal博士在印度Panjab大学获得生物化学学士学位，在华盛顿大学获得工商管理MBA学位，在罗格斯大学获得生物化学博士学位。我们相信Singhal博士在生物制药行业超过三十年的研发经验使他有资格担任Werewolf Therapeutics，Inc.董事会成员。
Anil Singhal has served on Werewolf Therapeutics, Inc. board of directors since February 2025. Since January 2021, Dr. Singhal has been serving as the President and Chief Executive Officer of Trishula Therapeutics, Inc., a private biotechnology company, where he also serves on its board of directors. From May 2019 to September 2020, Dr. Singhal served as the President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., or Adicet Bio, where he led the then private biotechnology company to its first oncology investigational new drug application submission and its merger with resTOR bio, Inc., which resulted in Adicet Bio becoming a public company. Dr. Singhal briefly served as an advisor to Adicet Bio from September 2020 to February 2021 following the merger. Dr. Singhal also served as Vice President, Early Oncology Development, of AbbVie Inc., a publicly traded pharmaceutical company, from January 2013 to March 2018. In addition, from July 2018 through September 2024, Dr. Singhal was a member of the board of directors of TriSalus Inc., a biotechnology company that became publicly traded in 2023. Dr. Singhal is a member of the American Association of Cancer Research, which he joined in 2005, and a member of the American Society of Clinical Oncology, which he joined in 2007. - Anil Singhal，自2025年2月起担任Werewolf Therapeutics，Inc.董事会成员。自2021年1月以来，Singhal博士一直担任私营生物技术公司Trishula Therapeutics，Inc.的总裁兼首席执行官，他还担任该公司的董事会成员。从2019年5月到2020年9月，Singhal博士担任Adicet Bio, Inc.或Adicet Bio的总裁兼首席执行官和董事会成员，在那里他带领这家当时的私营生物技术公司提交了首个肿瘤学研究性新药申请，并与RESTAR Bio，Inc.合并，这导致Adicet Bio成为一家上市公司。Singhal博士在合并后的2020年9月至2021年2月期间曾短暂担任Adicet Bio的顾问。Singhal博士还曾于2013年1月至2018年3月担任上市制药公司艾伯维公司（AbbVie Inc.）的早期肿瘤学开发副总裁。此外，从2018年7月到2024年9月，Singhal博士是TriSalus Inc.的董事会成员，该公司是一家于2023年上市的生物技术公司。Singhal博士是美国癌症研究协会的成员，他于2005年加入该协会，也是美国临床肿瘤学会的成员，他于2007年加入该协会。Singhal博士在印度Panjab大学获得生物化学学士学位，在华盛顿大学获得工商管理MBA学位，在罗格斯大学获得生物化学博士学位。我们相信Singhal博士在生物制药行业超过三十年的研发经验使他有资格担任Werewolf Therapeutics，Inc.董事会成员。
- Anil Singhal has served on Werewolf Therapeutics, Inc. board of directors since February 2025. Since January 2021, Dr. Singhal has been serving as the President and Chief Executive Officer of Trishula Therapeutics, Inc., a private biotechnology company, where he also serves on its board of directors. From May 2019 to September 2020, Dr. Singhal served as the President and Chief Executive Officer and a member of the board of directors of Adicet Bio, Inc., or Adicet Bio, where he led the then private biotechnology company to its first oncology investigational new drug application submission and its merger with resTOR bio, Inc., which resulted in Adicet Bio becoming a public company. Dr. Singhal briefly served as an advisor to Adicet Bio from September 2020 to February 2021 following the merger. Dr. Singhal also served as Vice President, Early Oncology Development, of AbbVie Inc., a publicly traded pharmaceutical company, from January 2013 to March 2018. In addition, from July 2018 through September 2024, Dr. Singhal was a member of the board of directors of TriSalus Inc., a biotechnology company that became publicly traded in 2023. Dr. Singhal is a member of the American Association of Cancer Research, which he joined in 2005, and a member of the American Society of Clinical Oncology, which he joined in 2007.
- Meeta Chatterjee
-
Meeta Chatterjee，自2021年10月起担任董事会成员。Chatterjee博士自2023年8月起担任Sun Pharmaceutical Industries Ltd.的首席战略官。Chatterjee博士此前于2019年3月至2022年11月期间担任传奇生物技术公司全球业务发展高级副总裁。2007年11月至2018年5月，她在跨国制药公司默克制药公司的一个部门默沙东研究实验室担任资历增加和责任增加的职务，最近担任业务发展和许可（BD & L）集团内的战略、交易和运营主管。Chatterjee博士此前曾于2020年12月至2024年12月在上市的临床阶段生物技术公司Editas Medicine的董事会任职。Chatterjee博士在印度艾哈迈达巴德的圣泽维尔大学和罗格斯大学（B.A.，Hons Physics）接受本科教育。Chatterjee博士在罗格斯大学获得了生理学哲学博士学位，并在弗吉尼亚大学医学院完成了生理学系的博士后研究金。
Meeta Chatterjee has served on Werewolf Therapeutics, Inc. board of directors since October 2021. Dr. Chatterjee previously was the Chief Strategy Officer of Sun Pharmaceutical Industries Ltd. from August 2023 to November 2025. Prior to that, Dr. Chatterjee served as the Senior Vice President of Global Business Development at Legend Biotech Corporation from March 2019 until November 2022. From November 2007 to May 2018, she served in roles of increasing seniority and responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., a multinational pharmaceutical company, most recently as Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group. Dr. Chatterjee served on the board of directors of Editas Medicine, a publicly traded clinical stage biotechnology company, from December 2020 to December 2024. - Meeta Chatterjee，自2021年10月起担任董事会成员。Chatterjee博士自2023年8月起担任Sun Pharmaceutical Industries Ltd.的首席战略官。Chatterjee博士此前于2019年3月至2022年11月期间担任传奇生物技术公司全球业务发展高级副总裁。2007年11月至2018年5月，她在跨国制药公司默克制药公司的一个部门默沙东研究实验室担任资历增加和责任增加的职务，最近担任业务发展和许可（BD & L）集团内的战略、交易和运营主管。Chatterjee博士此前曾于2020年12月至2024年12月在上市的临床阶段生物技术公司Editas Medicine的董事会任职。Chatterjee博士在印度艾哈迈达巴德的圣泽维尔大学和罗格斯大学（B.A.，Hons Physics）接受本科教育。Chatterjee博士在罗格斯大学获得了生理学哲学博士学位，并在弗吉尼亚大学医学院完成了生理学系的博士后研究金。
- Meeta Chatterjee has served on Werewolf Therapeutics, Inc. board of directors since October 2021. Dr. Chatterjee previously was the Chief Strategy Officer of Sun Pharmaceutical Industries Ltd. from August 2023 to November 2025. Prior to that, Dr. Chatterjee served as the Senior Vice President of Global Business Development at Legend Biotech Corporation from March 2019 until November 2022. From November 2007 to May 2018, she served in roles of increasing seniority and responsibility at Merck Research Laboratories, a division of Merck & Co., Inc., a multinational pharmaceutical company, most recently as Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group. Dr. Chatterjee served on the board of directors of Editas Medicine, a publicly traded clinical stage biotechnology company, from December 2020 to December 2024.
- Michael B. Atkins
-
Michael B. Atkins，自2018年8月起担任科学顾问委员会成员，自2024年1月起担任董事会成员。Atkins博士自2012年起担任乔治敦Lombardi综合癌症中心副主任和William M. Scholl乔治敦大学医学中心肿瘤科教授和副主席。他也是MedStar乔治敦大学医院血液肿瘤科的正式医师。在2012年搬到乔治敦大学之前，他于1987年在塔夫茨医疗中心开始了他的职业生涯，之后于1997年4月搬到贝斯以色列女执事医疗中心，并于2002年被任命为哈佛医学院教授。在Beth Israel Deaconess，他曾担任血液学/肿瘤学部副主任、生物治疗和皮肤肿瘤学项目的负责人，以及哈佛皮肤癌SPORE的联合PI，以及达纳 Farber/哈佛癌症中心肾癌项目的创始负责人和DF/HCC肾癌SPORE的主任。他是癌症免疫疗法协会（SITC）的前任主席，也是NCI重组DNA咨询委员会和ASCO提名委员会的前任成员。阿特金斯博士是黑色素瘤Research Alliance医学咨询小组主席、科学咨询委员会联合主席以及黑色素瘤研究基金会董事会成员。他于2021年获得OnClive颁发的癌症治疗巨擘奖——黑色素瘤，于2022年获得SITC颁发的终身成就奖，于2023年入选免疫肿瘤学会院士，并于2024年入选美国临床肿瘤学会（ASCO）院士。Atkins博士拥有塔夫茨大学化学学士学位和塔夫茨医学院医学博士学位。他在塔夫茨-新英格兰医学中心完成了内科住院医师培训和血液学/肿瘤学研究金。
Michael B. Atkins has served on Werewolf Therapeutics, Inc. Scientific Advisory Board since August 2018 and on Werewolf Therapeutics, Inc. board of directors since January 2024. Dr. Atkins has served as the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center and William M. Scholl Professor and Vice Chair of the Department of Oncology at Georgetown University Medical Center since 2012. He is also a staff physician in the Division of Hematology Oncology at MedStar Georgetown University Hospital. Prior to moving to Georgetown in 2012, he began his career at Tufts Medical Center in 1987 before moving to Beth Israel Deaconess Medical Center in April 1997 and being appointed Professor at Harvard Medical School in 2002. At Beth Israel Deaconess he served as Deputy Chief of the Division of Hematology/Oncology and leader of the Biologic Therapy and Cutaneous Oncology Programs, as well as Co PI of the Harvard Skin Cancer SPORE, and founding leader of the Dana Farber/Harvard Cancer Center Kidney Cancer Program and Director of the DF/HCC Kidney Cancer SPORE. He is past president of the Society for Immunotherapy of Cancer (SITC) and past member of the NCI Recombinant DNA Advisory Committee and the ASCO Nominating Committee. Dr. Atkins is Chair of the Medical Advisory Panel for the Melanoma Research Alliance, and co chair of the Scientific Advisory Committee and a Board member for the Melanoma Research Foundation. He received the Giant in Cancer Therapy Award Melanoma from OncLive in 2021, the Lifetime Achievement Award from SITC in 2022, was inducted as a Fellow in the Academy of ImmunoOncology in 2023 and as an American Society of Clinical Oncology (ASCO) Fellow in 2024. Dr. Atkins has a B.S. in chemistry from Tufts University and an M.D. from Tufts Medical School. He completed residency training in internal medicine and a fellowship in Hematology/Oncology at Tufts New England Medical Center. - Michael B. Atkins，自2018年8月起担任科学顾问委员会成员，自2024年1月起担任董事会成员。Atkins博士自2012年起担任乔治敦Lombardi综合癌症中心副主任和William M. Scholl乔治敦大学医学中心肿瘤科教授和副主席。他也是MedStar乔治敦大学医院血液肿瘤科的正式医师。在2012年搬到乔治敦大学之前，他于1987年在塔夫茨医疗中心开始了他的职业生涯，之后于1997年4月搬到贝斯以色列女执事医疗中心，并于2002年被任命为哈佛医学院教授。在Beth Israel Deaconess，他曾担任血液学/肿瘤学部副主任、生物治疗和皮肤肿瘤学项目的负责人，以及哈佛皮肤癌SPORE的联合PI，以及达纳 Farber/哈佛癌症中心肾癌项目的创始负责人和DF/HCC肾癌SPORE的主任。他是癌症免疫疗法协会（SITC）的前任主席，也是NCI重组DNA咨询委员会和ASCO提名委员会的前任成员。阿特金斯博士是黑色素瘤Research Alliance医学咨询小组主席、科学咨询委员会联合主席以及黑色素瘤研究基金会董事会成员。他于2021年获得OnClive颁发的癌症治疗巨擘奖——黑色素瘤，于2022年获得SITC颁发的终身成就奖，于2023年入选免疫肿瘤学会院士，并于2024年入选美国临床肿瘤学会（ASCO）院士。Atkins博士拥有塔夫茨大学化学学士学位和塔夫茨医学院医学博士学位。他在塔夫茨-新英格兰医学中心完成了内科住院医师培训和血液学/肿瘤学研究金。
- Michael B. Atkins has served on Werewolf Therapeutics, Inc. Scientific Advisory Board since August 2018 and on Werewolf Therapeutics, Inc. board of directors since January 2024. Dr. Atkins has served as the Deputy Director of the Georgetown Lombardi Comprehensive Cancer Center and William M. Scholl Professor and Vice Chair of the Department of Oncology at Georgetown University Medical Center since 2012. He is also a staff physician in the Division of Hematology Oncology at MedStar Georgetown University Hospital. Prior to moving to Georgetown in 2012, he began his career at Tufts Medical Center in 1987 before moving to Beth Israel Deaconess Medical Center in April 1997 and being appointed Professor at Harvard Medical School in 2002. At Beth Israel Deaconess he served as Deputy Chief of the Division of Hematology/Oncology and leader of the Biologic Therapy and Cutaneous Oncology Programs, as well as Co PI of the Harvard Skin Cancer SPORE, and founding leader of the Dana Farber/Harvard Cancer Center Kidney Cancer Program and Director of the DF/HCC Kidney Cancer SPORE. He is past president of the Society for Immunotherapy of Cancer (SITC) and past member of the NCI Recombinant DNA Advisory Committee and the ASCO Nominating Committee. Dr. Atkins is Chair of the Medical Advisory Panel for the Melanoma Research Alliance, and co chair of the Scientific Advisory Committee and a Board member for the Melanoma Research Foundation. He received the Giant in Cancer Therapy Award Melanoma from OncLive in 2021, the Lifetime Achievement Award from SITC in 2022, was inducted as a Fellow in the Academy of ImmunoOncology in 2023 and as an American Society of Clinical Oncology (ASCO) Fellow in 2024. Dr. Atkins has a B.S. in chemistry from Tufts University and an M.D. from Tufts Medical School. He completed residency training in internal medicine and a fellowship in Hematology/Oncology at Tufts New England Medical Center.
高管简历
中英对照 | 中文 | 英文- Daniel J. Hicklin
Daniel J.Hicklin自2019年8月起担任我们的总裁兼首席执行官。Hicklin博士于2017年10月创立了Werewolf Therapeutics，并担任顾问，直到被任命为我们的总裁兼首席执行官。此前，Hicklin博士是私营生物技术公司Potenza Therapeutics，Inc.的创始人，并于2014年4月至2018年12月被Astellas Pharma Inc.收购之前担任其总裁兼首席执行官。Hicklin从2013年8月到2014年2月担任Costim Pharmaceuticals，Inc.（一家私营生物技术公司，2014年2月被Novartis收购）总裁和首席科学官。Hicklin博士还于2014年至2019年12月担任执行合伙人，并自2020年1月起担任MPM Capital的顾问。加入Costim Pharmaceuticals之前，Hicklin在Merck Research Laboratories（前身为Schering-Plough Research Institute，被Merck收购之前）担任多个职位，包括领导肿瘤学生物制剂战略和免疫调节发现团队。Hicklin博士此前还在Imclone Systems Incorporated担任过多个职位，包括Vice President、实验治疗。Hicklin博士曾担任多家私营生物技术公司的董事会成员。Hicklin博士目前还在Mark Foundation for Cancer Research的行业咨询委员会任职。Hicklin博士拥有纽约医学院（New York Medical College）的微生物学和免疫学硕士学位和博士学位，在那里他与Soldano Ferrone博士一起接受培训，并获得爱荷华大学（University of Iowa）的B.S.学位。
Daniel J. Hicklin has served on Werewolf Therapeutics, Inc. board of directors since October 2017. Dr. Hicklin has also served as Werewolf Therapeutics, Inc. President and Chief Executive Officer since August 2019. Dr. Hicklin founded Werewolf Therapeutics in October 2017 and served as a consultant until his appointment as Werewolf Therapeutics, Inc. President and Chief Executive Officer. Dr. Hicklin also served as an Executive Partner at MPM Capital from 2014 to December 2019 and an advisor from January 2020 to December 2022. Previously, Dr. Hicklin was a founder of Potenza Therapeutics, Inc., a privately held biotechnology company, and served as its President and Chief Executive Officer from April 2014 until its acquisition by Astellas Pharma Inc. in December 2018. From August 2013 until February 2014, Dr. Hicklin was President and Chief Scientific Officer of CoStim Pharmaceuticals, Inc., a privately held biotechnology company that was acquired by Novartis in February 2014. Prior to joining CoStim Pharmaceuticals, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering Plough Research Institute prior to its acquisition by Merck), including leading its Biologics Strategy for Oncology and the Immuno Modulation Discovery team. Dr. Hicklin also previously held several positions at Imclone Systems Incorporated, including Vice President, Experimental Therapeutics. Dr. Hicklin has served as a member of the board of directors of several private biotechnology companies. Dr. Hicklin also currently serves on the Industry Advisory Committee for The Mark Foundation for Cancer Research. Dr. Hicklin holds an M.S. and Ph.D. in Microbiology and Immunology from New York Medical College, where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa.- Daniel J.Hicklin自2019年8月起担任我们的总裁兼首席执行官。Hicklin博士于2017年10月创立了Werewolf Therapeutics，并担任顾问，直到被任命为我们的总裁兼首席执行官。此前，Hicklin博士是私营生物技术公司Potenza Therapeutics，Inc.的创始人，并于2014年4月至2018年12月被Astellas Pharma Inc.收购之前担任其总裁兼首席执行官。Hicklin从2013年8月到2014年2月担任Costim Pharmaceuticals，Inc.（一家私营生物技术公司，2014年2月被Novartis收购）总裁和首席科学官。Hicklin博士还于2014年至2019年12月担任执行合伙人，并自2020年1月起担任MPM Capital的顾问。加入Costim Pharmaceuticals之前，Hicklin在Merck Research Laboratories（前身为Schering-Plough Research Institute，被Merck收购之前）担任多个职位，包括领导肿瘤学生物制剂战略和免疫调节发现团队。Hicklin博士此前还在Imclone Systems Incorporated担任过多个职位，包括Vice President、实验治疗。Hicklin博士曾担任多家私营生物技术公司的董事会成员。Hicklin博士目前还在Mark Foundation for Cancer Research的行业咨询委员会任职。Hicklin博士拥有纽约医学院（New York Medical College）的微生物学和免疫学硕士学位和博士学位，在那里他与Soldano Ferrone博士一起接受培训，并获得爱荷华大学（University of Iowa）的B.S.学位。
- Daniel J. Hicklin has served on Werewolf Therapeutics, Inc. board of directors since October 2017. Dr. Hicklin has also served as Werewolf Therapeutics, Inc. President and Chief Executive Officer since August 2019. Dr. Hicklin founded Werewolf Therapeutics in October 2017 and served as a consultant until his appointment as Werewolf Therapeutics, Inc. President and Chief Executive Officer. Dr. Hicklin also served as an Executive Partner at MPM Capital from 2014 to December 2019 and an advisor from January 2020 to December 2022. Previously, Dr. Hicklin was a founder of Potenza Therapeutics, Inc., a privately held biotechnology company, and served as its President and Chief Executive Officer from April 2014 until its acquisition by Astellas Pharma Inc. in December 2018. From August 2013 until February 2014, Dr. Hicklin was President and Chief Scientific Officer of CoStim Pharmaceuticals, Inc., a privately held biotechnology company that was acquired by Novartis in February 2014. Prior to joining CoStim Pharmaceuticals, Dr. Hicklin held several positions at Merck Research Laboratories (formerly the Schering Plough Research Institute prior to its acquisition by Merck), including leading its Biologics Strategy for Oncology and the Immuno Modulation Discovery team. Dr. Hicklin also previously held several positions at Imclone Systems Incorporated, including Vice President, Experimental Therapeutics. Dr. Hicklin has served as a member of the board of directors of several private biotechnology companies. Dr. Hicklin also currently serves on the Industry Advisory Committee for The Mark Foundation for Cancer Research. Dr. Hicklin holds an M.S. and Ph.D. in Microbiology and Immunology from New York Medical College, where he trained with Dr. Soldano Ferrone, and a B.S. from the University of Iowa.
- Steven Bloom
Steven Bloom，自2025年4月起担任首席商务官。此前，从2023年7月到2025年4月，Bloom先生在Vincerx Pharma, Inc.担任首席商务官，该公司是一家临床阶段ADC肿瘤产品平台公司，专注于业务发展、商业评估和公司战略。在此之前，他于2022年1月至2023年7月担任Transgene SA的首席商务官，该公司是一家临床阶段生物技术公司，开发专注于溶瘤病毒和癌症疫苗疗法的双平台；于2021年1月至2022年1月担任临床阶段生物技术公司Boston Pharmaceuticals，Inc.的首席商务官；于2019年11月至2020年12月担任专注于肿瘤学的生物技术公司Vavotar Life Sciences，LLC的首席商务官。他此前曾在礼来和公司担任市场营销、患者宣传和公司事务方面的高级职务。Bloom先生担任CLL Society的董事会主席，这是一个非营利组织，通过患者教育、倡导、支持和研究，解决慢性淋巴细胞白血病和小型淋巴细胞淋巴瘤社区未满足的需求。布卢姆先生在东北大学药学院获得了学士学位。
Steven Bloom has served as Werewolf Therapeutics, Inc. Chief Business Officer since April 2025. Previously, from July 2023 until April 2025, Mr. Bloom was Chief Business Officer at Vincerx Pharma, Inc., a clinical stage ADC oncology product platform company, focusing on business development, commercial assessment, and corporate strategy. Prior to that, he was Chief Business Officer at Transgene SA, a clinical stage biotechnology company developing twin platforms focused on oncolytic viruses and cancer vaccine therapies from January 2022 to July 2023; Chief Business Officer at Boston Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2021 to January 2022; and Chief Business Officer at Vavotar Life Sciences, LLC, an oncology focused biotechnology company, from November 2019 to December 2020. He previously held senior roles in marketing, patient advocacy, and corporate affairs at Eli Lilly and Company. Mr. Bloom serves as the Chair of the Board of CLL Society, a nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma community through patient education, advocacy, support, and research. Mr. Bloom earned a B.S. at the Northeastern University College of Pharmacy.- Steven Bloom，自2025年4月起担任首席商务官。此前，从2023年7月到2025年4月，Bloom先生在Vincerx Pharma, Inc.担任首席商务官，该公司是一家临床阶段ADC肿瘤产品平台公司，专注于业务发展、商业评估和公司战略。在此之前，他于2022年1月至2023年7月担任Transgene SA的首席商务官，该公司是一家临床阶段生物技术公司，开发专注于溶瘤病毒和癌症疫苗疗法的双平台；于2021年1月至2022年1月担任临床阶段生物技术公司Boston Pharmaceuticals，Inc.的首席商务官；于2019年11月至2020年12月担任专注于肿瘤学的生物技术公司Vavotar Life Sciences，LLC的首席商务官。他此前曾在礼来和公司担任市场营销、患者宣传和公司事务方面的高级职务。Bloom先生担任CLL Society的董事会主席，这是一个非营利组织，通过患者教育、倡导、支持和研究，解决慢性淋巴细胞白血病和小型淋巴细胞淋巴瘤社区未满足的需求。布卢姆先生在东北大学药学院获得了学士学位。
- Steven Bloom has served as Werewolf Therapeutics, Inc. Chief Business Officer since April 2025. Previously, from July 2023 until April 2025, Mr. Bloom was Chief Business Officer at Vincerx Pharma, Inc., a clinical stage ADC oncology product platform company, focusing on business development, commercial assessment, and corporate strategy. Prior to that, he was Chief Business Officer at Transgene SA, a clinical stage biotechnology company developing twin platforms focused on oncolytic viruses and cancer vaccine therapies from January 2022 to July 2023; Chief Business Officer at Boston Pharmaceuticals, Inc., a clinical stage biotechnology company, from January 2021 to January 2022; and Chief Business Officer at Vavotar Life Sciences, LLC, an oncology focused biotechnology company, from November 2019 to December 2020. He previously held senior roles in marketing, patient advocacy, and corporate affairs at Eli Lilly and Company. Mr. Bloom serves as the Chair of the Board of CLL Society, a nonprofit organization that addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma community through patient education, advocacy, support, and research. Mr. Bloom earned a B.S. at the Northeastern University College of Pharmacy.
- Michael Urban
Michael Urban，自2023年5月起担任公司财务副总裁、公司控制人。在加入公司之前，2021年3月至2023年4月，Urban先生曾在生物技术公司Codiak BioSciences，Inc.担任高级董事、公司控制人和设施主管。此前，Urban先生曾在2019年1月至2021年2月期间担任农业科技公司Indigo AG，Inc.的财务总监和公司财务总监。Urban先生拥有易三仓大学会计学和金融学学士学位，是一名注册会计师。
Michael Urban has served as Werewolf Therapeutics, Inc. Vice President of Finance and Corporate Controller since May 2023. Effective February 13, 2026, Mr. Urban was appointed as Werewolf Therapeutics, Inc. principal financial officer and principal accounting officer. Prior to joining the Company, from March 2021 to April 2023, Mr. Urban served as Senior Director, Corporate Controller and Head of Facilities at Codiak BioSciences, Inc., a biotechnology company. Previously, Mr. Urban served as Director of Finance and Corporate Controller at Indigo Ag, Inc., an agricultural technology company from January 2019 until February 2021. Mr. Urban holds a B.S. in accounting and finance from Assumption University and is a Certified Public Accountant.- Michael Urban，自2023年5月起担任公司财务副总裁、公司控制人。在加入公司之前，2021年3月至2023年4月，Urban先生曾在生物技术公司Codiak BioSciences，Inc.担任高级董事、公司控制人和设施主管。此前，Urban先生曾在2019年1月至2021年2月期间担任农业科技公司Indigo AG，Inc.的财务总监和公司财务总监。Urban先生拥有易三仓大学会计学和金融学学士学位，是一名注册会计师。
- Michael Urban has served as Werewolf Therapeutics, Inc. Vice President of Finance and Corporate Controller since May 2023. Effective February 13, 2026, Mr. Urban was appointed as Werewolf Therapeutics, Inc. principal financial officer and principal accounting officer. Prior to joining the Company, from March 2021 to April 2023, Mr. Urban served as Senior Director, Corporate Controller and Head of Facilities at Codiak BioSciences, Inc., a biotechnology company. Previously, Mr. Urban served as Director of Finance and Corporate Controller at Indigo Ag, Inc., an agricultural technology company from January 2019 until February 2021. Mr. Urban holds a B.S. in accounting and finance from Assumption University and is a Certified Public Accountant.